Risk Revolution: Fuzzy Logic, Risk Management, and Critical Thinking in Pharmaceuticals
Listen now
Description
In this episode, Stacey is joined by series coordinator Nuala Calnan and regular contributor Valerie Mulholland to discuss the book "Foundations in Quality Risk Management" with the author, Dr. Tim Sandle. One of the key topics of discussion is dealing with "Fuzzy Logic", and how to manage situations that appear vague, and how that applies to the Pharmaceutical and Healthcare industries. Welcome to Risk Revolution, a monthly series of the Voices in Validation podcast, brought to you by the IVT Network. The goal of this series is to advance the maturity of risk management practices within the industry, by covering topics that challenge quality professionals to seek opportunities to improve and advance the ways in which they perceive and manage risk. Resources from this episode: The ICH Q9 (R1) Guidelines ICH Q9 (R1) Presentation Can Fuzzy Logic Be Applied to Risk Management Critical Thinking #1: Why Pharmaceuticals and Healthcare Needs ... Critical Thinking #2: Reading Research Papers Critical Thinking #3: Developing Questions to Achieve the Optimal ... Risk Management, Knowledge Management and the Risk Knowledge Infinity Cycle on Risk Revolution Risk Revolution - Getting to the Root of the Matter Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.   
More Episodes
The pharmaceutical quality control laboratory serves one of the most important functions in pharmaceutical production and control. Poor laboratory practice may yield compliance issues, higher costs, increased cycle time, and delayed product introductions. Avoiding all that means consistent lab...
Published 04/05/22
Published 04/05/22
The much-discussed revision to the EU GMP Annex 1 is expected to be published early this year, bringing some major changes to drug developers’ current process and manufacturing methods for sterile products. Although the draft revision has been widely shared and commented on, it is still unclear...
Published 03/29/22